Adamis Reports APC-300 Kills Human Prostate Cancer Cells

SAN DIEGO--(BUSINESS WIRE)--Jul 20, 2011 - Adamis Pharmaceuticals Corporation (OTCBB: ADMP) announced today that in addition to activity in pancreatic cancer and its multiple modes of action, APC-300 significantly inhibits the growth of prostate cancer cells.

In 2010, the American Cancer Society reported that 217,730 men in the U.S. were diagnosed with prostate cancer and 32,050 were projected to die from the disease. While treatment with surgery and/or radiation is often successful, about one-third of patients will experience disease recurrence. Despite the initial success of androgen deprivation therapy (castration), prostate cancer continues to progress from androgen-dependent prostate cancer (ADPC) to castrate-resistant prostate cancer (CRPC) in most of these patients within a matter of years. More and more data point to the fact that androgen receptor (AR) plays a central role in both ADPC and CRPC. Therefore, identifying inhibitors of AR signaling which can act independent of hormonal status is of prime importance. These types of inhibitors could prove to be very important in the treatment of prostate cancer and thereby prevent or delay ADPC from progressing to CRPC. Based on the most recent information, APC-300 could very well be a molecule that acts independent of hormonal status.

A study published in Clinical Cancer Research (June 28, 2011) and authored by Dr. Mohammad Saleem and his associates from the Hormel Institute, University of Minnesota and the Mayo Clinic showed that APC-300 inhibits AR signaling and activation in prostate cancer in both ADPC and CRPC. Agents that have the potential to combat prostate cancer under both conditions (androgen and non-androgen responsive environments) are rare, but obviously desirable. APC-300 has been shown to have this desired activity. The results of the current study are significant because they demonstrate that APC-300, while sparing normal cells, preferentially inhibits the growth and proliferation of heterogeneous prostate cancer cells representing differential androgen sensitivity and AR expression status. Also, the observation that APC-300 sensitized highly aggressive CRPC cells to bicalutamide (currently used to treat ADPC) has high clinical relevance.

Additionally, APC-300 was shown to decrease messenger RNA and protein expression of the AR-target gene, PSA (biomarker for prostate cancer) in ADPC and CRPC cells. This translated into APC-300 showing a decrease in the secreted levels of PSA in a concentration dependent manner and a decrease in the growth of prostate cancer cells in vitro and in vivo. The data provide good evidence that APC-300 has the potential to decrease the AR transcriptional activity of ADPC and CRPC cells by blocking the AR occupancy on AR-responsive elements in target genes. The data also show that APC-300 had a significant effect on reducing the growth of ADPC and CRPC and reducing the levels of PSA in the mouse tumor model. Taken together, these data suggest that APC-300 may very well play a significant role in the treatment of prostate cancer.

Dennis J. Carlo, Ph.D., President and CEO of Adamis, states that, “We continue to build upon our prostate cancer franchise. New independent published data validate the importance of our three compounds (APC-100, 200, 300) for the treatment of prostate and pancreatic cancer. We will continue to focus and aggressively move these compounds into the clinic. Molecules such as APC-300 could very well work alone, but also just as important, APC-300 may enhance the activity of compounds already marketed and used for the treatment of prostate cancer.”

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations or future financial performance, including, but not limited to the following statements: the company's beliefs concerning the safety and effectiveness of the compounds and drug product candidates described in this press release; the results of any future clinical trials that the company may conduct relating to the licensed compounds; the ability to fund future product development; future revenues expected from any of the licensed compounds, assuming that they are developed and approved for marketing by the FDA and other regulatory authorities; and the intellectual property protection that may be afforded by any patents or patent applications relating to the licensed technology. Statements in this press release concerning future milestone events depend on several factors beyond the company's control, including receipt of adequate funding to support these activities. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis' actual results to be materially different from these forward-looking statements. Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis' filings from time to time with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Adamis expressly disclaims any intent to update any forward-looking statements.

 

Contact: Capital Group Communications, Inc.
Mark Gundy, 415-332-7200
mark.gundy@capitalgc.com

 

 

Posted: July 2011

View comments

Hide
(web3)